Florida Senate - 2021 COMMITTEE AMENDMENT
Bill No. SB 1476
Ì706830ÈÎ706830
LEGISLATIVE ACTION
Senate . House
.
.
.
.
.
—————————————————————————————————————————————————————————————————
—————————————————————————————————————————————————————————————————
The Committee on Rules (Brodeur) recommended the following:
1 Senate Amendment (with title amendment)
2
3 Delete lines 12 - 25
4 and insert:
5 Section 1. Paragraph (c) of subsection (1) and paragraph
6 (d) of subsection (5) of section 893.03, Florida Statutes, are
7 amended to read:
8 893.03 Standards and schedules.—The substances enumerated
9 in this section are controlled by this chapter. The controlled
10 substances listed or to be listed in Schedules I, II, III, IV,
11 and V are included by whatever official, common, usual,
12 chemical, trade name, or class designated. The provisions of
13 this section shall not be construed to include within any of the
14 schedules contained in this section any excluded drugs listed
15 within the purview of 21 C.F.R. s. 1308.22, styled “Excluded
16 Substances”; 21 C.F.R. s. 1308.24, styled “Exempt Chemical
17 Preparations”; 21 C.F.R. s. 1308.32, styled “Exempted
18 Prescription Products”; or 21 C.F.R. s. 1308.34, styled “Exempt
19 Anabolic Steroid Products.”
20 (1) SCHEDULE I.—A substance in Schedule I has a high
21 potential for abuse and has no currently accepted medical use in
22 treatment in the United States and in its use under medical
23 supervision does not meet accepted safety standards. The
24 following substances are controlled in Schedule I:
25 (c) Unless specifically excepted or unless listed in
26 another schedule, any material, compound, mixture, or
27 preparation that contains any quantity of the following
28 hallucinogenic substances or that contains any of their salts,
29 isomers, including optical, positional, or geometric isomers,
30 homologues, nitrogen-heterocyclic analogs, esters, ethers, and
31 salts of isomers, homologues, nitrogen-heterocyclic analogs,
32 esters, or ethers, if the existence of such salts, isomers, and
33 salts of isomers is possible within the specific chemical
34 designation or class description:
35 1. Alpha-Ethyltryptamine.
36 2. 4-Methylaminorex (2-Amino-4-methyl-5-phenyl-2
37 oxazoline).
38 3. Aminorex (2-Amino-5-phenyl-2-oxazoline).
39 4. DOB (4-Bromo-2,5-dimethoxyamphetamine).
40 5. 2C-B (4-Bromo-2,5-dimethoxyphenethylamine).
41 6. Bufotenine.
42 7. Cannabis, except if it is contained within a
43 pharmaceutical product approved by the United States Food and
44 Drug Administration.
45 8. Cathinone.
46 9. DET (Diethyltryptamine).
47 10. 2,5-Dimethoxyamphetamine.
48 11. DOET (4-Ethyl-2,5-Dimethoxyamphetamine).
49 12. DMT (Dimethyltryptamine).
50 13. PCE (N-Ethyl-1-phenylcyclohexylamine) (Ethylamine
51 analog of phencyclidine).
52 14. JB-318 (N-Ethyl-3-piperidyl benzilate).
53 15. N-Ethylamphetamine.
54 16. Fenethylline.
55 17. 3,4-Methylenedioxy-N-hydroxyamphetamine.
56 18. Ibogaine.
57 19. LSD (Lysergic acid diethylamide).
58 20. Mescaline.
59 21. Methcathinone.
60 22. 5-Methoxy-3,4-methylenedioxyamphetamine.
61 23. PMA (4-Methoxyamphetamine).
62 24. PMMA (4-Methoxymethamphetamine).
63 25. DOM (4-Methyl-2,5-dimethoxyamphetamine).
64 26. MDEA (3,4-Methylenedioxy-N-ethylamphetamine).
65 27. MDA (3,4-Methylenedioxyamphetamine).
66 28. JB-336 (N-Methyl-3-piperidyl benzilate).
67 29. N,N-Dimethylamphetamine.
68 30. Parahexyl.
69 31. Peyote.
70 32. PCPY (N-(1-Phenylcyclohexyl)-pyrrolidine) (Pyrrolidine
71 analog of phencyclidine).
72 33. Psilocybin.
73 34. Psilocyn.
74 35. Salvia divinorum, except for any drug product approved
75 by the United States Food and Drug Administration which contains
76 Salvia divinorum or its isomers, esters, ethers, salts, and
77 salts of isomers, esters, and ethers, if the existence of such
78 isomers, esters, ethers, and salts is possible within the
79 specific chemical designation.
80 36. Salvinorin A, except for any drug product approved by
81 the United States Food and Drug Administration which contains
82 Salvinorin A or its isomers, esters, ethers, salts, and salts of
83 isomers, esters, and ethers, if the existence of such isomers,
84 esters, ethers, and salts is possible within the specific
85 chemical designation.
86 37. Xylazine.
87 38. TCP (1-[1-(2-Thienyl)-cyclohexyl]-piperidine)
88 (Thiophene analog of phencyclidine).
89 39. 3,4,5-Trimethoxyamphetamine.
90 40. Methylone (3,4-Methylenedioxymethcathinone).
91 41. MDPV (3,4-Methylenedioxypyrovalerone).
92 42. Methylmethcathinone.
93 43. Methoxymethcathinone.
94 44. Fluoromethcathinone.
95 45. Methylethcathinone.
96 46. CP 47,497 (2-(3-Hydroxycyclohexyl)-5-(2-methyloctan-2
97 yl)phenol) and its dimethyloctyl (C8) homologue.
98 47. HU-210 [(6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-(2
99 methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol].
100 48. JWH-018 (1-Pentyl-3-(1-naphthoyl)indole).
101 49. JWH-073 (1-Butyl-3-(1-naphthoyl)indole).
102 50. JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1
103 naphthoyl)indole).
104 51. BZP (Benzylpiperazine).
105 52. Fluorophenylpiperazine.
106 53. Methylphenylpiperazine.
107 54. Chlorophenylpiperazine.
108 55. Methoxyphenylpiperazine.
109 56. DBZP (1,4-Dibenzylpiperazine).
110 57. TFMPP (Trifluoromethylphenylpiperazine).
111 58. MBDB (Methylbenzodioxolylbutanamine) or (3,4
112 Methylenedioxy-N-methylbutanamine).
113 59. 5-Hydroxy-AMT (5-Hydroxy-alpha-methyltryptamine).
114 60. 5-Hydroxy-N-methyltryptamine.
115 61. 5-MeO-MiPT (5-Methoxy-N-methyl-N-isopropyltryptamine).
116 62. 5-MeO-AMT (5-Methoxy-alpha-methyltryptamine).
117 63. Methyltryptamine.
118 64. 5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine).
119 65. 5-Me-DMT (5-Methyl-N,N-dimethyltryptamine).
120 66. Tyramine (4-Hydroxyphenethylamine).
121 67. 5-MeO-DiPT (5-Methoxy-N,N-Diisopropyltryptamine).
122 68. DiPT (N,N-Diisopropyltryptamine).
123 69. DPT (N,N-Dipropyltryptamine).
124 70. 4-Hydroxy-DiPT (4-Hydroxy-N,N-diisopropyltryptamine).
125 71. 5-MeO-DALT (5-Methoxy-N,N-Diallyltryptamine).
126 72. DOI (4-Iodo-2,5-dimethoxyamphetamine).
127 73. DOC (4-Chloro-2,5-dimethoxyamphetamine).
128 74. 2C-E (4-Ethyl-2,5-dimethoxyphenethylamine).
129 75. 2C-T-4 (4-Isopropylthio-2,5-dimethoxyphenethylamine).
130 76. 2C-C (4-Chloro-2,5-dimethoxyphenethylamine).
131 77. 2C-T (4-Methylthio-2,5-dimethoxyphenethylamine).
132 78. 2C-T-2 (4-Ethylthio-2,5-dimethoxyphenethylamine).
133 79. 2C-T-7 (4-(n)-Propylthio-2,5-dimethoxyphenethylamine).
134 80. 2C-I (4-Iodo-2,5-dimethoxyphenethylamine).
135 81. Butylone (3,4-Methylenedioxy-alpha
136 methylaminobutyrophenone).
137 82. Ethcathinone.
138 83. Ethylone (3,4-Methylenedioxy-N-ethylcathinone).
139 84. Naphyrone (Naphthylpyrovalerone).
140 85. Dimethylone (3,4-Methylenedioxy-N,N-dimethylcathinone).
141 86. 3,4-Methylenedioxy-N,N-diethylcathinone.
142 87. 3,4-Methylenedioxy-propiophenone.
143 88. 3,4-Methylenedioxy-alpha-bromopropiophenone.
144 89. 3,4-Methylenedioxy-propiophenone-2-oxime.
145 90. 3,4-Methylenedioxy-N-acetylcathinone.
146 91. 3,4-Methylenedioxy-N-acetylmethcathinone.
147 92. 3,4-Methylenedioxy-N-acetylethcathinone.
148 93. Bromomethcathinone.
149 94. Buphedrone (alpha-Methylamino-butyrophenone).
150 95. Eutylone (3,4-Methylenedioxy-alpha
151 ethylaminobutyrophenone).
152 96. Dimethylcathinone.
153 97. Dimethylmethcathinone.
154 98. Pentylone (3,4-Methylenedioxy-alpha
155 methylaminovalerophenone).
156 99. MDPPP (3,4-Methylenedioxy-alpha
157 pyrrolidinopropiophenone).
158 100. MDPBP (3,4-Methylenedioxy-alpha
159 pyrrolidinobutyrophenone).
160 101. MOPPP (Methoxy-alpha-pyrrolidinopropiophenone).
161 102. MPHP (Methyl-alpha-pyrrolidinohexanophenone).
162 103. BTCP (Benzothiophenylcyclohexylpiperidine) or BCP
163 (Benocyclidine).
164 104. F-MABP (Fluoromethylaminobutyrophenone).
165 105. MeO-PBP (Methoxypyrrolidinobutyrophenone).
166 106. Et-PBP (Ethylpyrrolidinobutyrophenone).
167 107. 3-Me-4-MeO-MCAT (3-Methyl-4-Methoxymethcathinone).
168 108. Me-EABP (Methylethylaminobutyrophenone).
169 109. Etizolam.
170 110. PPP (Pyrrolidinopropiophenone).
171 111. PBP (Pyrrolidinobutyrophenone).
172 112. PVP (Pyrrolidinovalerophenone) or
173 (Pyrrolidinopentiophenone).
174 113. MPPP (Methyl-alpha-pyrrolidinopropiophenone).
175 114. JWH-007 (1-Pentyl-2-methyl-3-(1-naphthoyl)indole).
176 115. JWH-015 (1-Propyl-2-methyl-3-(1-naphthoyl)indole).
177 116. JWH-019 (1-Hexyl-3-(1-naphthoyl)indole).
178 117. JWH-020 (1-Heptyl-3-(1-naphthoyl)indole).
179 118. JWH-072 (1-Propyl-3-(1-naphthoyl)indole).
180 119. JWH-081 (1-Pentyl-3-(4-methoxy-1-naphthoyl)indole).
181 120. JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole).
182 121. JWH-133 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methylpentan
183 2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
184 122. JWH-175 (1-Pentyl-3-(1-naphthylmethyl)indole).
185 123. JWH-201 (1-Pentyl-3-(4-methoxyphenylacetyl)indole).
186 124. JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole).
187 125. JWH-210 (1-Pentyl-3-(4-ethyl-1-naphthoyl)indole).
188 126. JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole).
189 127. JWH-251 (1-Pentyl-3-(2-methylphenylacetyl)indole).
190 128. JWH-302 (1-Pentyl-3-(3-methoxyphenylacetyl)indole).
191 129. JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole).
192 130. HU-211 ((6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-3
193 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1
194 ol).
195 131. HU-308 ([(1R,2R,5R)-2-[2,6-Dimethoxy-4-(2-methyloctan
196 2-yl)phenyl]-7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl]
197 methanol).
198 132. HU-331 (3-Hydroxy-2-[(1R,6R)-3-methyl-6-(1
199 methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-2,5-cyclohexadiene
200 1,4-dione).
201 133. CB-13 (4-Pentyloxy-1-(1-naphthoyl)naphthalene).
202 134. CB-25 (N-Cyclopropyl-11-(3-hydroxy-5-pentylphenoxy)
203 undecanamide).
204 135. CB-52 (N-Cyclopropyl-11-(2-hexyl-5-hydroxyphenoxy)
205 undecanamide).
206 136. CP 55,940 (2-[3-Hydroxy-6-propanol-cyclohexyl]-5-(2
207 methyloctan-2-yl)phenol).
208 137. AM-694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole).
209 138. AM-2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl)indole).
210 139. RCS-4 (1-Pentyl-3-(4-methoxybenzoyl)indole).
211 140. RCS-8 (1-(2-Cyclohexylethyl)-3-(2
212 methoxyphenylacetyl)indole).
213 141. WIN55,212-2 ((R)-(+)-[2,3-Dihydro-5-methyl-3-(4
214 morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1
215 naphthalenylmethanone).
216 142. WIN55,212-3 ([(3S)-2,3-Dihydro-5-methyl-3-(4
217 morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1
218 naphthalenylmethanone).
219 143. Pentedrone (alpha-Methylaminovalerophenone).
220 144. Fluoroamphetamine.
221 145. Fluoromethamphetamine.
222 146. Methoxetamine.
223 147. Methiopropamine.
224 148. Methylbuphedrone (Methyl-alpha
225 methylaminobutyrophenone).
226 149. APB ((2-Aminopropyl)benzofuran).
227 150. APDB ((2-Aminopropyl)-2,3-dihydrobenzofuran).
228 151. UR-144 (1-Pentyl-3-(2,2,3,3
229 tetramethylcyclopropanoyl)indole).
230 152. XLR11 (1-(5-Fluoropentyl)-3-(2,2,3,3
231 tetramethylcyclopropanoyl)indole).
232 153. Chloro UR-144 (1-(Chloropentyl)-3-(2,2,3,3
233 tetramethylcyclopropanoyl)indole).
234 154. AKB48 (N-Adamant-1-yl 1-pentylindazole-3-carboxamide).
235 155. AM-2233(1-[(N-Methyl-2-piperidinyl)methyl]-3-(2
236 iodobenzoyl)indole).
237 156. STS-135 (N-Adamant-1-yl 1-(5-fluoropentyl)indole-3
238 carboxamide).
239 157. URB-597 ((3′-(Aminocarbonyl)[1,1′-biphenyl]-3-yl)
240 cyclohexylcarbamate).
241 158. URB-602 ([1,1′-Biphenyl]-3-yl-carbamic acid,
242 cyclohexyl ester).
243 159. URB-754 (6-Methyl-2-[(4-methylphenyl)amino]-1
244 benzoxazin-4-one).
245 160. 2C-D (4-Methyl-2,5-dimethoxyphenethylamine).
246 161. 2C-H (2,5-Dimethoxyphenethylamine).
247 162. 2C-N (4-Nitro-2,5-dimethoxyphenethylamine).
248 163. 2C-P (4-(n)-Propyl-2,5-dimethoxyphenethylamine).
249 164. 25I-NBOMe (4-Iodo-2,5-dimethoxy-[N-(2
250 methoxybenzyl)]phenethylamine).
251 165. MDMA (3,4-Methylenedioxymethamphetamine).
252 166. PB-22 (8-Quinolinyl 1-pentylindole-3-carboxylate).
253 167. Fluoro PB-22 (8-Quinolinyl 1-(fluoropentyl)indole-3
254 carboxylate).
255 168. BB-22 (8-Quinolinyl 1-(cyclohexylmethyl)indole-3
256 carboxylate).
257 169. Fluoro AKB48 (N-Adamant-1-yl 1-(fluoropentyl)indazole
258 3-carboxamide).
259 170. AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
260 pentylindazole-3-carboxamide).
261 171. AB-FUBINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
262 (4-fluorobenzyl)indazole-3-carboxamide).
263 172. ADB-PINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)
264 1-pentylindazole-3-carboxamide).
265 173. Fluoro ADBICA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2
266 yl)-1-(fluoropentyl)indole-3-carboxamide).
267 174. 25B-NBOMe (4-Bromo-2,5-dimethoxy-[N-(2
268 methoxybenzyl)]phenethylamine).
269 175. 25C-NBOMe (4-Chloro-2,5-dimethoxy-[N-(2
270 methoxybenzyl)]phenethylamine).
271 176. AB-CHMINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
272 (cyclohexylmethyl)indazole-3-carboxamide).
273 177. FUB-PB-22 (8-Quinolinyl 1-(4-fluorobenzyl)indole-3
274 carboxylate).
275 178. Fluoro-NNEI (N-Naphthalen-1-yl 1-(fluoropentyl)indole
276 3-carboxamide).
277 179. Fluoro-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1
278 (fluoropentyl)indazole-3-carboxamide).
279 180. THJ-2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl)indazole).
280 181. AM-855 ((4aR,12bR)-8-Hexyl-2,5,5-trimethyl
281 1,4,4a,8,9,10,11,12b-octahydronaphtho[3,2-c]isochromen-12-ol).
282 182. AM-905 ((6aR,9R,10aR)-3-[(E)-Hept-1-enyl]-9
283 (hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a
284 hexahydrobenzo[c]chromen-1-ol).
285 183. AM-906 ((6aR,9R,10aR)-3-[(Z)-Hept-1-enyl]-9
286 (hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a
287 hexahydrobenzo[c]chromen-1-ol).
288 184. AM-2389 ((6aR,9R,10aR)-3-(1-Hexyl-cyclobut-1-yl)
289 6a,7,8,9,10,10a-hexahydro-6,6-dimethyl-6H-dibenzo[b,d]pyran-1,9
290 diol).
291 185. HU-243 ((6aR,8S,9S,10aR)-9-(Hydroxymethyl)-6,6
292 dimethyl-3-(2-methyloctan-2-yl)-8,9-ditritio-7,8,10,10a
293 tetrahydro-6aH-benzo[c]chromen-1-ol).
294 186. HU-336 ((6aR,10aR)-6,6,9-Trimethyl-3-pentyl
295 6a,7,10,10a-tetrahydro-1H-benzo[c]chromene-1,4(6H)-dione).
296 187. MAPB ((2-Methylaminopropyl)benzofuran).
297 188. 5-IT (2-(1H-Indol-5-yl)-1-methyl-ethylamine).
298 189. 6-IT (2-(1H-Indol-6-yl)-1-methyl-ethylamine).
299 190. Synthetic Cannabinoids.—Unless specifically excepted
300 or unless listed in another schedule or contained within a
301 pharmaceutical product approved by the United States Food and
302 Drug Administration, any material, compound, mixture, or
303 preparation that contains any quantity of a synthetic
304 cannabinoid found to be in any of the following chemical class
305 descriptions, or homologues, nitrogen-heterocyclic analogs,
306 isomers (including optical, positional, or geometric), esters,
307 ethers, salts, and salts of homologues, nitrogen-heterocyclic
308 analogs, isomers, esters, or ethers, whenever the existence of
309 such homologues, nitrogen-heterocyclic analogs, isomers, esters,
310 ethers, salts, and salts of isomers, esters, or ethers is
311 possible within the specific chemical class or designation.
312 Since nomenclature of these synthetically produced cannabinoids
313 is not internationally standardized and may continually evolve,
314 these structures or the compounds of these structures shall be
315 included under this subparagraph, regardless of their specific
316 numerical designation of atomic positions covered, if it can be
317 determined through a recognized method of scientific testing or
318 analysis that the substance contains properties that fit within
319 one or more of the following categories:
320 a. Tetrahydrocannabinols.—Any tetrahydrocannabinols
321 naturally contained in a plant of the genus Cannabis, the
322 synthetic equivalents of the substances contained in the plant
323 or in the resinous extracts of the genus Cannabis, or synthetic
324 substances, derivatives, and their isomers with similar chemical
325 structure and pharmacological activity, including, but not
326 limited to, Delta 9 tetrahydrocannabinols and their optical
327 isomers, Delta 8 tetrahydrocannabinols and their optical
328 isomers, Delta 6a,10a tetrahydrocannabinols and their optical
329 isomers, or any compound containing a tetrahydrobenzo[c]chromene
330 structure with substitution at either or both the 3-position or
331 9-position, with or without substitution at the 1-position with
332 hydroxyl or alkoxy groups, including, but not limited to:
333 (I) Tetrahydrocannabinol.
334 (II) HU-210 ((6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3
335 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1
336 ol).
337 (III) HU-211 ((6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-3
338 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1
339 ol).
340 (IV) JWH-051 ((6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3
341 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
342 (V) JWH-133 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methylpentan
343 2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
344 (VI) JWH-057 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methyloctan
345 2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
346 (VII) JWH-359 ((6aR,10aR)-1-Methoxy-6,6,9-trimethyl-3-(2,3
347 dimethylpentan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
348 (VIII) AM-087 ((6aR,10aR)-3-(2-Methyl-6-bromohex-2-yl)
349 6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol).
350 (IX) AM-411 ((6aR,10aR)-3-(1-Adamantyl)-6,6,9-trimethyl
351 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol).
352 (X) Parahexyl.
353 b. Naphthoylindoles, Naphthoylindazoles,
354 Naphthoylcarbazoles, Naphthylmethylindoles,
355 Naphthylmethylindazoles, and Naphthylmethylcarbazoles.—Any
356 compound containing a naphthoylindole, naphthoylindazole,
357 naphthoylcarbazole, naphthylmethylindole,
358 naphthylmethylindazole, or naphthylmethylcarbazole structure,
359 with or without substitution on the indole, indazole, or
360 carbazole ring to any extent, whether or not substituted on the
361 naphthyl ring to any extent, including, but not limited to:
362 (I) JWH-007 (1-Pentyl-2-methyl-3-(1-naphthoyl)indole).
363 (II) JWH-011 (1-(1-Methylhexyl)-2-methyl-3-(1
364 naphthoyl)indole).
365 (III) JWH-015 (1-Propyl-2-methyl-3-(1-naphthoyl)indole).
366 (IV) JWH-016 (1-Butyl-2-methyl-3-(1-naphthoyl)indole).
367 (V) JWH-018 (1-Pentyl-3-(1-naphthoyl)indole).
368 (VI) JWH-019 (1-Hexyl-3-(1-naphthoyl)indole).
369 (VII) JWH-020 (1-Heptyl-3-(1-naphthoyl)indole).
370 (VIII) JWH-022 (1-(4-Pentenyl)-3-(1-naphthoyl)indole).
371 (IX) JWH-071 (1-Ethyl-3-(1-naphthoyl)indole).
372 (X) JWH-072 (1-Propyl-3-(1-naphthoyl)indole).
373 (XI) JWH-073 (1-Butyl-3-(1-naphthoyl)indole).
374 (XII) JWH-080 (1-Butyl-3-(4-methoxy-1-naphthoyl)indole).
375 (XIII) JWH-081 (1-Pentyl-3-(4-methoxy-1-naphthoyl)indole).
376 (XIV) JWH-098 (1-Pentyl-2-methyl-3-(4-methoxy-1
377 naphthoyl)indole).
378 (XV) JWH-116 (1-Pentyl-2-ethyl-3-(1-naphthoyl)indole).
379 (XVI) JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole).
380 (XVII) JWH-149 (1-Pentyl-2-methyl-3-(4-methyl-1
381 naphthoyl)indole).
382 (XVIII) JWH-164 (1-Pentyl-3-(7-methoxy-1-naphthoyl)indole).
383 (XIX) JWH-175 (1-Pentyl-3-(1-naphthylmethyl)indole).
384 (XX) JWH-180 (1-Propyl-3-(4-propyl-1-naphthoyl)indole).
385 (XXI) JWH-182 (1-Pentyl-3-(4-propyl-1-naphthoyl)indole).
386 (XXII) JWH-184 (1-Pentyl-3-[(4-methyl)-1
387 naphthylmethyl]indole).
388 (XXIII) JWH-193 (1-[2-(4-Morpholinyl)ethyl]-3-(4-methyl-1
389 naphthoyl)indole).
390 (XXIV) JWH-198 (1-[2-(4-Morpholinyl)ethyl]-3-(4-methoxy-1
391 naphthoyl)indole).
392 (XXV) JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1
393 naphthoyl)indole).
394 (XXVI) JWH-210 (1-Pentyl-3-(4-ethyl-1-naphthoyl)indole).
395 (XXVII) JWH-387 (1-Pentyl-3-(4-bromo-1-naphthoyl)indole).
396 (XXVIII) JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole).
397 (XXIX) JWH-412 (1-Pentyl-3-(4-fluoro-1-naphthoyl)indole).
398 (XXX) JWH-424 (1-Pentyl-3-(8-bromo-1-naphthoyl)indole).
399 (XXXI) AM-1220 (1-[(1-Methyl-2-piperidinyl)methyl]-3-(1
400 naphthoyl)indole).
401 (XXXII) AM-1235 (1-(5-Fluoropentyl)-6-nitro-3-(1
402 naphthoyl)indole).
403 (XXXIII) AM-2201 (1-(5-Fluoropentyl)-3-(1
404 naphthoyl)indole).
405 (XXXIV) Chloro JWH-018 (1-(Chloropentyl)-3-(1
406 naphthoyl)indole).
407 (XXXV) Bromo JWH-018 (1-(Bromopentyl)-3-(1
408 naphthoyl)indole).
409 (XXXVI) AM-2232 (1-(4-Cyanobutyl)-3-(1-naphthoyl)indole).
410 (XXXVII) THJ-2201 (1-(5-Fluoropentyl)-3-(1
411 naphthoyl)indazole).
412 (XXXVIII) MAM-2201 (1-(5-Fluoropentyl)-3-(4-methyl-1
413 naphthoyl)indole).
414 (XXXIX) EAM-2201 (1-(5-Fluoropentyl)-3-(4-ethyl-1
415 naphthoyl)indole).
416 (XL) EG-018 (9-Pentyl-3-(1-naphthoyl)carbazole).
417 (XLI) EG-2201 (9-(5-Fluoropentyl)-3-(1
418 naphthoyl)carbazole).
419 c. Naphthoylpyrroles.—Any compound containing a
420 naphthoylpyrrole structure, with or without substitution on the
421 pyrrole ring to any extent, whether or not substituted on the
422 naphthyl ring to any extent, including, but not limited to:
423 (I) JWH-030 (1-Pentyl-3-(1-naphthoyl)pyrrole).
424 (II) JWH-031 (1-Hexyl-3-(1-naphthoyl)pyrrole).
425 (III) JWH-145 (1-Pentyl-5-phenyl-3-(1-naphthoyl)pyrrole).
426 (IV) JWH-146 (1-Heptyl-5-phenyl-3-(1-naphthoyl)pyrrole).
427 (V) JWH-147 (1-Hexyl-5-phenyl-3-(1-naphthoyl)pyrrole).
428 (VI) JWH-307 (1-Pentyl-5-(2-fluorophenyl)-3-(1
429 naphthoyl)pyrrole).
430 (VII) JWH-309 (1-Pentyl-5-(1-naphthalenyl)-3-(1
431 naphthoyl)pyrrole).
432 (VIII) JWH-368 (1-Pentyl-5-(3-fluorophenyl)-3-(1
433 naphthoyl)pyrrole).
434 (IX) JWH-369 (1-Pentyl-5-(2-chlorophenyl)-3-(1
435 naphthoyl)pyrrole).
436 (X) JWH-370 (1-Pentyl-5-(2-methylphenyl)-3-(1
437 naphthoyl)pyrrole).
438 d. Naphthylmethylenindenes.—Any compound containing a
439 naphthylmethylenindene structure, with or without substitution
440 at the 3-position of the indene ring to any extent, whether or
441 not substituted on the naphthyl ring to any extent, including,
442 but not limited to, JWH-176 (3-Pentyl-1
443 (naphthylmethylene)indene).
444 e. Phenylacetylindoles and Phenylacetylindazoles.—Any
445 compound containing a phenylacetylindole or phenylacetylindazole
446 structure, with or without substitution on the indole or
447 indazole ring to any extent, whether or not substituted on the
448 phenyl ring to any extent, including, but not limited to:
449 (I) JWH-167 (1-Pentyl-3-(phenylacetyl)indole).
450 (II) JWH-201 (1-Pentyl-3-(4-methoxyphenylacetyl)indole).
451 (III) JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole).
452 (IV) JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole).
453 (V) JWH-251 (1-Pentyl-3-(2-methylphenylacetyl)indole).
454 (VI) JWH-302 (1-Pentyl-3-(3-methoxyphenylacetyl)indole).
455 (VII) Cannabipiperidiethanone.
456 (VIII) RCS-8 (1-(2-Cyclohexylethyl)-3-(2
457 methoxyphenylacetyl)indole).
458 f. Cyclohexylphenols.—Any compound containing a
459 cyclohexylphenol structure, with or without substitution at the
460 5-position of the phenolic ring to any extent, whether or not
461 substituted on the cyclohexyl ring to any extent, including, but
462 not limited to:
463 (I) CP 47,497 (2-(3-Hydroxycyclohexyl)-5-(2-methyloctan-2
464 yl)phenol).
465 (II) Cannabicyclohexanol (CP 47,497 dimethyloctyl (C8)
466 homologue).
467 (III) CP-55,940 (2-(3-Hydroxy-6-propanol-cyclohexyl)-5-(2
468 methyloctan-2-yl)phenol).
469 g. Benzoylindoles and Benzoylindazoles.—Any compound
470 containing a benzoylindole or benzoylindazole structure, with or
471 without substitution on the indole or indazole ring to any
472 extent, whether or not substituted on the phenyl ring to any
473 extent, including, but not limited to:
474 (I) AM-679 (1-Pentyl-3-(2-iodobenzoyl)indole).
475 (II) AM-694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole).
476 (III) AM-1241 (1-[(N-Methyl-2-piperidinyl)methyl]-3-(2
477 iodo-5-nitrobenzoyl)indole).
478 (IV) Pravadoline (1-[2-(4-Morpholinyl)ethyl]-2-methyl-3-(4
479 methoxybenzoyl)indole).
480 (V) AM-2233 (1-[(N-Methyl-2-piperidinyl)methyl]-3-(2
481 iodobenzoyl)indole).
482 (VI) RCS-4 (1-Pentyl-3-(4-methoxybenzoyl)indole).
483 (VII) RCS-4 C4 homologue (1-Butyl-3-(4
484 methoxybenzoyl)indole).
485 (VIII) AM-630 (1-[2-(4-Morpholinyl)ethyl]-2-methyl-6-iodo
486 3-(4-methoxybenzoyl)indole).
487 h. Tetramethylcyclopropanoylindoles and
488 Tetramethylcyclopropanoylindazoles.—Any compound containing a
489 tetramethylcyclopropanoylindole or
490 tetramethylcyclopropanoylindazole structure, with or without
491 substitution on the indole or indazole ring to any extent,
492 whether or not substituted on the tetramethylcyclopropyl group
493 to any extent, including, but not limited to:
494 (I) UR-144 (1-Pentyl-3-(2,2,3,3
495 tetramethylcyclopropanoyl)indole).
496 (II) XLR11 (1-(5-Fluoropentyl)-3-(2,2,3,3
497 tetramethylcyclopropanoyl)indole).
498 (III) Chloro UR-144 (1-(Chloropentyl)-3-(2,2,3,3
499 tetramethylcyclopropanoyl)indole).
500 (IV) A-796,260 (1-[2-(4-Morpholinyl)ethyl]-3-(2,2,3,3
501 tetramethylcyclopropanoyl)indole).
502 (V) A-834,735 (1-[4-(Tetrahydropyranyl)methyl]-3-(2,2,3,3
503 tetramethylcyclopropanoyl)indole).
504 (VI) M-144 (1-(5-Fluoropentyl)-2-methyl-3-(2,2,3,3
505 tetramethylcyclopropanoyl)indole).
506 (VII) FUB-144 (1-(4-Fluorobenzyl)-3-(2,2,3,3
507 tetramethylcyclopropanoyl)indole).
508 (VIII) FAB-144 (1-(5-Fluoropentyl)-3-(2,2,3,3
509 tetramethylcyclopropanoyl)indazole).
510 (IX) XLR12 (1-(4,4,4-Trifluorobutyl)-3-(2,2,3,3
511 tetramethylcyclopropanoyl)indole).
512 (X) AB-005 (1-[(1-Methyl-2-piperidinyl)methyl]-3-(2,2,3,3
513 tetramethylcyclopropanoyl)indole).
514 i. Adamantoylindoles, Adamantoylindazoles, Adamantylindole
515 carboxamides, and Adamantylindazole carboxamides.—Any compound
516 containing an adamantoyl indole, adamantoyl indazole, adamantyl
517 indole carboxamide, or adamantyl indazole carboxamide structure,
518 with or without substitution on the indole or indazole ring to
519 any extent, whether or not substituted on the adamantyl ring to
520 any extent, including, but not limited to:
521 (I) AKB48 (N-Adamant-1-yl 1-pentylindazole-3-carboxamide).
522 (II) Fluoro AKB48 (N-Adamant-1-yl 1-(fluoropentyl)indazole
523 3-carboxamide).
524 (III) STS-135 (N-Adamant-1-yl 1-(5-fluoropentyl)indole-3
525 carboxamide).
526 (IV) AM-1248 (1-(1-Methylpiperidine)methyl-3-(1
527 adamantoyl)indole).
528 (V) AB-001 (1-Pentyl-3-(1-adamantoyl)indole).
529 (VI) APICA (N-Adamant-1-yl 1-pentylindole-3-carboxamide).
530 (VII) Fluoro AB-001 (1-(Fluoropentyl)-3-(1
531 adamantoyl)indole).
532 j. Quinolinylindolecarboxylates,
533 Quinolinylindazolecarboxylates, Quinolinylindolecarboxamides,
534 and Quinolinylindazolecarboxamides.—Any compound containing a
535 quinolinylindole carboxylate, quinolinylindazole carboxylate,
536 isoquinolinylindole carboxylate, isoquinolinylindazole
537 carboxylate, quinolinylindole carboxamide, quinolinylindazole
538 carboxamide, isoquinolinylindole carboxamide, or
539 isoquinolinylindazole carboxamide structure, with or without
540 substitution on the indole or indazole ring to any extent,
541 whether or not substituted on the quinoline or isoquinoline ring
542 to any extent, including, but not limited to:
543 (I) PB-22 (8-Quinolinyl 1-pentylindole-3-carboxylate).
544 (II) Fluoro PB-22 (8-Quinolinyl 1-(fluoropentyl)indole-3
545 carboxylate).
546 (III) BB-22 (8-Quinolinyl 1-(cyclohexylmethyl)indole-3
547 carboxylate).
548 (IV) FUB-PB-22 (8-Quinolinyl 1-(4-fluorobenzyl)indole-3
549 carboxylate).
550 (V) NPB-22 (8-Quinolinyl 1-pentylindazole-3-carboxylate).
551 (VI) Fluoro NPB-22 (8-Quinolinyl 1-(fluoropentyl)indazole
552 3-carboxylate).
553 (VII) FUB-NPB-22 (8-Quinolinyl 1-(4-fluorobenzyl)indazole
554 3-carboxylate).
555 (VIII) THJ (8-Quinolinyl 1-pentylindazole-3-carboxamide).
556 (IX) Fluoro THJ (8-Quinolinyl 1-(fluoropentyl)indazole-3
557 carboxamide).
558 k. Naphthylindolecarboxylates and
559 Naphthylindazolecarboxylates.—Any compound containing a
560 naphthylindole carboxylate or naphthylindazole carboxylate
561 structure, with or without substitution on the indole or
562 indazole ring to any extent, whether or not substituted on the
563 naphthyl ring to any extent, including, but not limited to:
564 (I) NM-2201 (1-Naphthalenyl 1-(5-fluoropentyl)indole-3
565 carboxylate).
566 (II) SDB-005 (1-Naphthalenyl 1-pentylindazole-3
567 carboxylate).
568 (III) Fluoro SDB-005 (1-Naphthalenyl 1
569 (fluoropentyl)indazole-3-carboxylate).
570 (IV) FDU-PB-22 (1-Naphthalenyl 1-(4-fluorobenzyl)indole-3
571 carboxylate).
572 (V) 3-CAF (2-Naphthalenyl 1-(2-fluorophenyl)indazole-3
573 carboxylate).
574 l. Naphthylindole carboxamides and Naphthylindazole
575 carboxamides.—Any compound containing a naphthylindole
576 carboxamide or naphthylindazole carboxamide structure, with or
577 without substitution on the indole or indazole ring to any
578 extent, whether or not substituted on the naphthyl ring to any
579 extent, including, but not limited to:
580 (I) NNEI (N-Naphthalen-1-yl 1-pentylindole-3-carboxamide).
581 (II) Fluoro-NNEI (N-Naphthalen-1-yl 1-(fluoropentyl)indole
582 3-carboxamide).
583 (III) Chloro-NNEI (N-Naphthalen-1-yl 1
584 (chloropentyl)indole-3-carboxamide).
585 (IV) MN-18 (N-Naphthalen-1-yl 1-pentylindazole-3
586 carboxamide).
587 (V) Fluoro MN-18 (N-Naphthalen-1-yl 1
588 (fluoropentyl)indazole-3-carboxamide).
589 m. Alkylcarbonyl indole carboxamides, Alkylcarbonyl
590 indazole carboxamides, Alkylcarbonyl indole carboxylates, and
591 Alkylcarbonyl indazole carboxylates.—Any compound containing an
592 alkylcarbonyl group, including 1-amino-3-methyl-1-oxobutan-2-yl,
593 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-amino-1-oxo-3
594 phenylpropan-2-yl, 1-methoxy-1-oxo-3-phenylpropan-2-yl, with an
595 indole carboxamide, indazole carboxamide, indole carboxylate, or
596 indazole carboxylate, with or without substitution on the indole
597 or indazole ring to any extent, whether or not substituted on
598 the alkylcarbonyl group to any extent, including, but not
599 limited to:
600 (I) ADBICA, (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1
601 pentylindole-3-carboxamide).
602 (II) Fluoro ADBICA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2
603 yl)-1-(fluoropentyl)indole-3-carboxamide).
604 (III) Fluoro ABICA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
605 (fluoropentyl)indole-3-carboxamide).
606 (IV) AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
607 pentylindazole-3-carboxamide).
608 (V) Fluoro AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)
609 1-(fluoropentyl)indazole-3-carboxamide).
610 (VI) ADB-PINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)
611 1-pentylindazole-3-carboxamide).
612 (VII) Fluoro ADB-PINACA (N-(1-Amino-3,3-dimethyl-1
613 oxobutan-2-yl)-1-(fluoropentyl)indazole-3-carboxamide).
614 (VIII) AB-FUBINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
615 (4-fluorobenzyl)indazole-3-carboxamide).
616 (IX) ADB-FUBINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2
617 yl)-1-(4-fluorobenzyl)indazole-3-carboxamide).
618 (X) AB-CHMINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
619 (cyclohexylmethyl)indazole-3-carboxamide).
620 (XI) MA-CHMINACA (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1
621 (cyclohexylmethyl)indazole-3-carboxamide).
622 (XII) MAB-CHMINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2
623 yl)-1-(cyclohexylmethyl)indazole-3-carboxamide).
624 (XIII) AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1
625 pentylindazole-3-carboxamide).
626 (XIV) Fluoro-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1
627 (fluoropentyl)indazole-3-carboxamide).
628 (XV) FUB-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1-(4
629 fluorobenzyl)indazole-3-carboxamide).
630 (XVI) MDMB-CHMINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan
631 2-yl)-1-(cyclohexylmethyl)indazole-3-carboxamide).
632 (XVII) MDMB-FUBINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan
633 2-yl)-1-(4-fluorobenzyl)indazole-3-carboxamide).
634 (XVIII) MDMB-CHMICA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan
635 2-yl)-1-(cyclohexylmethyl)indole-3-carboxamide).
636 (XIX) PX-1 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5
637 fluoropentyl)indole-3-carboxamide).
638 (XX) PX-2 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5
639 fluoropentyl)indazole-3-carboxamide).
640 (XXI) PX-3 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1
641 (cyclohexylmethyl)indazole-3-carboxamide).
642 (XXII) PX-4 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(4
643 fluorobenzyl)indazole-3-carboxamide).
644 (XXIII) MO-CHMINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan
645 2-yl)-1-(cyclohexylmethyl)indazole-3-carboxylate).
646 n. Cumylindolecarboxamides and Cumylindazolecarboxamides.
647 Any compound containing a N-(2-phenylpropan-2-yl) indole
648 carboxamide or N-(2-phenylpropan-2-yl) indazole carboxamide
649 structure, with or without substitution on the indole or
650 indazole ring to any extent, whether or not substituted on the
651 phenyl ring of the cumyl group to any extent, including, but not
652 limited to:
653 (I) CUMYL-PICA (N-(2-Phenylpropan-2-yl)-1-pentylindole-3
654 carboxamide).
655 (II) Fluoro CUMYL-PICA (N-(2-Phenylpropan-2-yl)-1
656 (fluoropentyl)indole-3-carboxamide).
657 o. Other Synthetic Cannabinoids.—Any material, compound,
658 mixture, or preparation that contains any quantity of a
659 Synthetic Cannabinoid, as described in sub-subparagraphs a.-n.:
660 (I) With or without modification or replacement of a
661 carbonyl, carboxamide, alkylene, alkyl, or carboxylate linkage
662 between either two core rings, or linkage between a core ring
663 and group structure, with or without the addition of a carbon or
664 replacement of a carbon;
665 (II) With or without replacement of a core ring or group
666 structure, whether or not substituted on the ring or group
667 structures to any extent; and
668 (III) Is a cannabinoid receptor agonist, unless
669 specifically excepted or unless listed in another schedule or
670 contained within a pharmaceutical product approved by the United
671 States Food and Drug Administration.
672 191. Substituted Cathinones.—Unless specifically excepted,
673 listed in another schedule, or contained within a pharmaceutical
674 product approved by the United States Food and Drug
675 Administration, any material, compound, mixture, or preparation,
676 including its salts, isomers, esters, or ethers, and salts of
677 isomers, esters, or ethers, whenever the existence of such salts
678 is possible within any of the following specific chemical
679 designations:
680 a. Any compound containing a 2-amino-1-phenyl-1-propanone
681 structure;
682 b. Any compound containing a 2-amino-1-naphthyl-1-propanone
683 structure; or
684 c. Any compound containing a 2-amino-1-thiophenyl-1
685 propanone structure,
686
687 whether or not the compound is further modified:
688 (I) With or without substitution on the ring system to any
689 extent with alkyl, alkylthio, thio, fused alkylenedioxy, alkoxy,
690 haloalkyl, hydroxyl, nitro, fused furan, fused benzofuran, fused
691 dihydrofuran, fused tetrahydropyran, fused alkyl ring, or halide
692 substituents;
693 (II) With or without substitution at the 3-propanone
694 position with an alkyl substituent or removal of the methyl
695 group at the 3-propanone position;
696 (III) With or without substitution at the 2-amino nitrogen
697 atom with alkyl, dialkyl, acetyl, or benzyl groups, whether or
698 not further substituted in the ring system; or
699 (IV) With or without inclusion of the 2-amino nitrogen atom
700 in a cyclic structure, including, but not limited to:
701 (A) Methcathinone.
702 (B) Ethcathinone.
703 (C) Methylone (3,4-Methylenedioxymethcathinone).
704 (D) 2,3-Methylenedioxymethcathinone.
705 (E) MDPV (3,4-Methylenedioxypyrovalerone).
706 (F) Methylmethcathinone.
707 (G) Methoxymethcathinone.
708 (H) Fluoromethcathinone.
709 (I) Methylethcathinone.
710 (J) Butylone (3,4-Methylenedioxy-alpha
711 methylaminobutyrophenone).
712 (K) Ethylone (3,4-Methylenedioxy-N-ethylcathinone).
713 (L) BMDP (3,4-Methylenedioxy-N-benzylcathinone).
714 (M) Naphyrone (Naphthylpyrovalerone).
715 (N) Bromomethcathinone.
716 (O) Buphedrone (alpha-Methylaminobutyrophenone).
717 (P) Eutylone (3,4-Methylenedioxy-alpha
718 ethylaminobutyrophenone).
719 (Q) Dimethylcathinone.
720 (R) Dimethylmethcathinone.
721 (S) Pentylone (3,4-Methylenedioxy-alpha
722 methylaminovalerophenone).
723 (T) Pentedrone (alpha-Methylaminovalerophenone).
724 (U) MDPPP (3,4-Methylenedioxy-alpha
725 pyrrolidinopropiophenone).
726 (V) MDPBP (3,4-Methylenedioxy-alpha
727 pyrrolidinobutyrophenone).
728 (W) MPPP (Methyl-alpha-pyrrolidinopropiophenone).
729 (X) PPP (Pyrrolidinopropiophenone).
730 (Y) PVP (Pyrrolidinovalerophenone) or
731 (Pyrrolidinopentiophenone).
732 (Z) MOPPP (Methoxy-alpha-pyrrolidinopropiophenone).
733 (AA) MPHP (Methyl-alpha-pyrrolidinohexanophenone).
734 (BB) F-MABP (Fluoromethylaminobutyrophenone).
735 (CC) Me-EABP (Methylethylaminobutyrophenone).
736 (DD) PBP (Pyrrolidinobutyrophenone).
737 (EE) MeO-PBP (Methoxypyrrolidinobutyrophenone).
738 (FF) Et-PBP (Ethylpyrrolidinobutyrophenone).
739 (GG) 3-Me-4-MeO-MCAT (3-Methyl-4-Methoxymethcathinone).
740 (HH) Dimethylone (3,4-Methylenedioxy-N,N
741 dimethylcathinone).
742 (II) 3,4-Methylenedioxy-N,N-diethylcathinone.
743 (JJ) 3,4-Methylenedioxy-N-acetylcathinone.
744 (KK) 3,4-Methylenedioxy-N-acetylmethcathinone.
745 (LL) 3,4-Methylenedioxy-N-acetylethcathinone.
746 (MM) Methylbuphedrone (Methyl-alpha
747 methylaminobutyrophenone).
748 (NN) Methyl-alpha-methylaminohexanophenone.
749 (OO) N-Ethyl-N-methylcathinone.
750 (PP) PHP (Pyrrolidinohexanophenone).
751 (QQ) PV8 (Pyrrolidinoheptanophenone).
752 (RR) Chloromethcathinone.
753 (SS) 4-Bromo-2,5-dimethoxy-alpha-aminoacetophenone.
754 192. Substituted Phenethylamines.—Unless specifically
755 excepted or unless listed in another schedule, or contained
756 within a pharmaceutical product approved by the United States
757 Food and Drug Administration, any material, compound, mixture,
758 or preparation, including its salts, isomers, esters, or ethers,
759 and salts of isomers, esters, or ethers, whenever the existence
760 of such salts is possible within any of the following specific
761 chemical designations, any compound containing a phenethylamine
762 structure, without a beta-keto group, and without a benzyl group
763 attached to the amine group, whether or not the compound is
764 further modified with or without substitution on the phenyl ring
765 to any extent with alkyl, alkylthio, nitro, alkoxy, thio,
766 halide, fused alkylenedioxy, fused furan, fused benzofuran,
767 fused dihydrofuran, or fused tetrahydropyran substituents,
768 whether or not further substituted on a ring to any extent, with
769 or without substitution at the alpha or beta position by any
770 alkyl substituent, with or without substitution at the nitrogen
771 atom, and with or without inclusion of the 2-amino nitrogen atom
772 in a cyclic structure, including, but not limited to:
773 a. 2C-B (4-Bromo-2,5-dimethoxyphenethylamine).
774 b. 2C-E (4-Ethyl-2,5-dimethoxyphenethylamine).
775 c. 2C-T-4 (4-Isopropylthio-2,5-dimethoxyphenethylamine).
776 d. 2C-C (4-Chloro-2,5-dimethoxyphenethylamine).
777 e. 2C-T (4-Methylthio-2,5-dimethoxyphenethylamine).
778 f. 2C-T-2 (4-Ethylthio-2,5-dimethoxyphenethylamine).
779 g. 2C-T-7 (4-(n)-Propylthio-2,5-dimethoxyphenethylamine).
780 h. 2C-I (4-Iodo-2,5-dimethoxyphenethylamine).
781 i. 2C-D (4-Methyl-2,5-dimethoxyphenethylamine).
782 j. 2C-H (2,5-Dimethoxyphenethylamine).
783 k. 2C-N (4-Nitro-2,5-dimethoxyphenethylamine).
784 l. 2C-P (4-(n)-Propyl-2,5-dimethoxyphenethylamine).
785 m. MDMA (3,4-Methylenedioxymethamphetamine).
786 n. MBDB (Methylbenzodioxolylbutanamine) or (3,4
787 Methylenedioxy-N-methylbutanamine).
788 o. MDA (3,4-Methylenedioxyamphetamine).
789 p. 2,5-Dimethoxyamphetamine.
790 q. Fluoroamphetamine.
791 r. Fluoromethamphetamine.
792 s. MDEA (3,4-Methylenedioxy-N-ethylamphetamine).
793 t. DOB (4-Bromo-2,5-dimethoxyamphetamine).
794 u. DOC (4-Chloro-2,5-dimethoxyamphetamine).
795 v. DOET (4-Ethyl-2,5-dimethoxyamphetamine).
796 w. DOI (4-Iodo-2,5-dimethoxyamphetamine).
797 x. DOM (4-Methyl-2,5-dimethoxyamphetamine).
798 y. PMA (4-Methoxyamphetamine).
799 z. N-Ethylamphetamine.
800 aa. 3,4-Methylenedioxy-N-hydroxyamphetamine.
801 bb. 5-Methoxy-3,4-methylenedioxyamphetamine.
802 cc. PMMA (4-Methoxymethamphetamine).
803 dd. N,N-Dimethylamphetamine.
804 ee. 3,4,5-Trimethoxyamphetamine.
805 ff. 4-APB (4-(2-Aminopropyl)benzofuran).
806 gg. 5-APB (5-(2-Aminopropyl)benzofuran).
807 hh. 6-APB (6-(2-Aminopropyl)benzofuran).
808 ii. 7-APB (7-(2-Aminopropyl)benzofuran).
809 jj. 4-APDB (4-(2-Aminopropyl)-2,3-dihydrobenzofuran).
810 kk. 5-APDB (5-(2-Aminopropyl)-2,3-dihydrobenzofuran).
811 ll. 6-APDB (6-(2-Aminopropyl)-2,3-dihydrobenzofuran).
812 mm. 7-APDB (7-(2-Aminopropyl)-2,3-dihydrobenzofuran).
813 nn. 4-MAPB (4-(2-Methylaminopropyl)benzofuran).
814 oo. 5-MAPB (5-(2-Methylaminopropyl)benzofuran).
815 pp. 6-MAPB (6-(2-Methylaminopropyl)benzofuran).
816 qq. 7-MAPB (7-(2-Methylaminopropyl)benzofuran).
817 rr. 5-EAPB (5-(2-Ethylaminopropyl)benzofuran).
818 ss. 5-MAPDB (5-(2-Methylaminopropyl)-2,3
819 dihydrobenzofuran),
820
821 which does not include phenethylamine, mescaline as described in
822 subparagraph 20., substituted cathinones as described in
823 subparagraph 191., N-Benzyl phenethylamine compounds as
824 described in subparagraph 193., or methamphetamine as described
825 in subparagraph (2)(c)5.
826 193. N-Benzyl Phenethylamine Compounds.—Unless specifically
827 excepted or unless listed in another schedule, or contained
828 within a pharmaceutical product approved by the United States
829 Food and Drug Administration, any material, compound, mixture,
830 or preparation, including its salts, isomers, esters, or ethers,
831 and salts of isomers, esters, or ethers, whenever the existence
832 of such salts is possible within any of the following specific
833 chemical designations, any compound containing a phenethylamine
834 structure without a beta-keto group, with substitution on the
835 nitrogen atom of the amino group with a benzyl substituent, with
836 or without substitution on the phenyl or benzyl ring to any
837 extent with alkyl, alkoxy, thio, alkylthio, halide, fused
838 alkylenedioxy, fused furan, fused benzofuran, or fused
839 tetrahydropyran substituents, whether or not further substituted
840 on a ring to any extent, with or without substitution at the
841 alpha position by any alkyl substituent, including, but not
842 limited to:
843 a. 25B-NBOMe (4-Bromo-2,5-dimethoxy-[N-(2
844 methoxybenzyl)]phenethylamine).
845 b. 25B-NBOH (4-Bromo-2,5-dimethoxy-[N-(2
846 hydroxybenzyl)]phenethylamine).
847 c. 25B-NBF (4-Bromo-2,5-dimethoxy-[N-(2
848 fluorobenzyl)]phenethylamine).
849 d. 25B-NBMD (4-Bromo-2,5-dimethoxy-[N-(2,3
850 methylenedioxybenzyl)]phenethylamine).
851 e. 25I-NBOMe (4-Iodo-2,5-dimethoxy-[N-(2
852 methoxybenzyl)]phenethylamine).
853 f. 25I-NBOH (4-Iodo-2,5-dimethoxy-[N-(2
854 hydroxybenzyl)]phenethylamine).
855 g. 25I-NBF (4-Iodo-2,5-dimethoxy-[N-(2
856 fluorobenzyl)]phenethylamine).
857 h. 25I-NBMD (4-Iodo-2,5-dimethoxy-[N-(2,3
858 methylenedioxybenzyl)]phenethylamine).
859 i. 25T2-NBOMe (4-Methylthio-2,5-dimethoxy-[N-(2
860 methoxybenzyl)]phenethylamine).
861 j. 25T4-NBOMe (4-Isopropylthio-2,5-dimethoxy-[N-(2
862 methoxybenzyl)]phenethylamine).
863 k. 25T7-NBOMe (4-(n)-Propylthio-2,5-dimethoxy-[N-(2
864 methoxybenzyl)]phenethylamine).
865 l. 25C-NBOMe (4-Chloro-2,5-dimethoxy-[N-(2
866 methoxybenzyl)]phenethylamine).
867 m. 25C-NBOH (4-Chloro-2,5-dimethoxy-[N-(2
868 hydroxybenzyl)]phenethylamine).
869 n. 25C-NBF (4-Chloro-2,5-dimethoxy-[N-(2
870 fluorobenzyl)]phenethylamine).
871 o. 25C-NBMD (4-Chloro-2,5-dimethoxy-[N-(2,3
872 methylenedioxybenzyl)]phenethylamine).
873 p. 25H-NBOMe (2,5-Dimethoxy-[N-(2
874 methoxybenzyl)]phenethylamine).
875 q. 25H-NBOH (2,5-Dimethoxy-[N-(2
876 hydroxybenzyl)]phenethylamine).
877 r. 25H-NBF (2,5-Dimethoxy-[N-(2
878 fluorobenzyl)]phenethylamine).
879 s. 25D-NBOMe (4-Methyl-2,5-dimethoxy-[N-(2
880 methoxybenzyl)]phenethylamine),
881
882 which does not include substituted cathinones as described in
883 subparagraph 191.
884 194. Substituted Tryptamines.—Unless specifically excepted
885 or unless listed in another schedule, or contained within a
886 pharmaceutical product approved by the United States Food and
887 Drug Administration, any material, compound, mixture, or
888 preparation containing a 2-(1H-indol-3-yl)ethanamine, for
889 example tryptamine, structure with or without mono- or di
890 substitution of the amine nitrogen with alkyl or alkenyl groups,
891 or by inclusion of the amino nitrogen atom in a cyclic
892 structure, whether or not substituted at the alpha position with
893 an alkyl group, whether or not substituted on the indole ring to
894 any extent with any alkyl, alkoxy, halo, hydroxyl, or acetoxy
895 groups, including, but not limited to:
896 a. Alpha-Ethyltryptamine.
897 b. Bufotenine.
898 c. DET (Diethyltryptamine).
899 d. DMT (Dimethyltryptamine).
900 e. MET (N-Methyl-N-ethyltryptamine).
901 f. DALT (N,N-Diallyltryptamine).
902 g. EiPT (N-Ethyl-N-isopropyltryptamine).
903 h. MiPT (N-Methyl-N-isopropyltryptamine).
904 i. 5-Hydroxy-AMT (5-Hydroxy-alpha-methyltryptamine).
905 j. 5-Hydroxy-N-methyltryptamine.
906 k. 5-MeO-MiPT (5-Methoxy-N-methyl-N-isopropyltryptamine).
907 l. 5-MeO-AMT (5-Methoxy-alpha-methyltryptamine).
908 m. Methyltryptamine.
909 n. 5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine).
910 o. 5-Me-DMT (5-Methyl-N,N-dimethyltryptamine).
911 p. 5-MeO-DiPT (5-Methoxy-N,N-Diisopropyltryptamine).
912 q. DiPT (N,N-Diisopropyltryptamine).
913 r. DPT (N,N-Dipropyltryptamine).
914 s. 4-Hydroxy-DiPT (4-Hydroxy-N,N-diisopropyltryptamine).
915 t. 5-MeO-DALT (5-Methoxy-N,N-Diallyltryptamine).
916 u. 4-AcO-DMT (4-Acetoxy-N,N-dimethyltryptamine).
917 v. 4-AcO-DiPT (4-Acetoxy-N,N-diisopropyltryptamine).
918 w. 4-Hydroxy-DET (4-Hydroxy-N,N-diethyltryptamine).
919 x. 4-Hydroxy-MET (4-Hydroxy-N-methyl-N-ethyltryptamine).
920 y. 4-Hydroxy-MiPT (4-Hydroxy-N-methyl-N
921 isopropyltryptamine).
922 z. Methyl-alpha-ethyltryptamine.
923 aa. Bromo-DALT (Bromo-N,N-diallyltryptamine),
924
925 which does not include tryptamine, psilocyn as described in
926 subparagraph 34., or psilocybin as described in subparagraph 33.
927 195. Substituted Phenylcyclohexylamines.—Unless
928 specifically excepted or unless listed in another schedule, or
929 contained within a pharmaceutical product approved by the United
930 States Food and Drug Administration, any material, compound,
931 mixture, or preparation containing a phenylcyclohexylamine
932 structure, with or without any substitution on the phenyl ring,
933 any substitution on the cyclohexyl ring, any replacement of the
934 phenyl ring with a thiophenyl or benzothiophenyl ring, with or
935 without substitution on the amine with alkyl, dialkyl, or alkoxy
936 substituents, inclusion of the nitrogen in a cyclic structure,
937 or any combination of the above, including, but not limited to:
938 a. BTCP (Benzothiophenylcyclohexylpiperidine) or BCP
939 (Benocyclidine).
940 b. PCE (N-Ethyl-1-phenylcyclohexylamine)(Ethylamine analog
941 of phencyclidine).
942 c. PCPY (N-(1-Phenylcyclohexyl)-pyrrolidine)(Pyrrolidine
943 analog of phencyclidine).
944 d. PCPr (Phenylcyclohexylpropylamine).
945 e. TCP (1-[1-(2-Thienyl)-cyclohexyl]-piperidine)(Thiophene
946 analog of phencyclidine).
947 f. PCEEA (Phenylcyclohexyl(ethoxyethylamine)).
948 g. PCMPA (Phenylcyclohexyl(methoxypropylamine)).
949 h. Methoxetamine.
950 i. 3-Methoxy-PCE ((3-Methoxyphenyl)cyclohexylethylamine).
951 j. Bromo-PCP ((Bromophenyl)cyclohexylpiperidine).
952 k. Chloro-PCP ((Chlorophenyl)cyclohexylpiperidine).
953 l. Fluoro-PCP ((Fluorophenyl)cyclohexylpiperidine).
954 m. Hydroxy-PCP ((Hydroxyphenyl)cyclohexylpiperidine).
955 n. Methoxy-PCP ((Methoxyphenyl)cyclohexylpiperidine).
956 o. Methyl-PCP ((Methylphenyl)cyclohexylpiperidine).
957 p. Nitro-PCP ((Nitrophenyl)cyclohexylpiperidine).
958 q. Oxo-PCP ((Oxophenyl)cyclohexylpiperidine).
959 r. Amino-PCP ((Aminophenyl)cyclohexylpiperidine).
960 196. W-15, 4-chloro-N-[1-(2-phenylethyl)-2
961 piperidinylidene]-benzenesulfonamide.
962 197. W-18, 4-chloro-N-[1-[2-(4-nitrophenyl)ethyl]-2
963 piperidinylidene]-benzenesulfonamide.
964 198. AH-7921, 3,4-dichloro-N-[[1
965 (dimethylamino)cyclohexyl]methyl]-benzamide.
966 199. U47700, trans-3,4-dichloro-N-[2
967 (dimethylamino)cyclohexyl]-N-methyl-benzamide.
968 200. MT-45, 1-cyclohexyl-4-(1,2-diphenylethyl)-piperazine,
969 dihydrochloride.
970
971 ================= T I T L E A M E N D M E N T ================
972 And the title is amended as follows:
973 Delete line 3
974 and insert:
975 893.03, F.S.; excluding from Schedule I cannabis if it
976 is contained within a pharmaceutical product approved
977 by the United States Food and Drug Administration;
978 removing from Schedule V certain drug